Skip to main content

Table 3 The relation of  EGFR  gene copy number status with progression-free survival and overall survival

From: EGFR gene copy number as a predictive biomarker for the treatment of metastatic colorectal cancer with anti-EGFR monoclonal antibodies: a meta-analysis

Study Median PFS (mo) HR  P  Median OS (mo) HR  P 
GCN + vs GCN- GCN + vs GCN-
Bengala 200925 -- -- NS -- -- NS
Campanella 201026 -- 0.54 0.03 -- -- --
Cappuzzo 200823 6.6 vs 3.5* -- 0.02 11.3 vs 8.5* -- 0.8
Goncalves 200829 4.1 vs 3.3 -- -- -- -- --
Italiano 200815 -- -- 0.70 -- -- 0.82
Khambata-Ford 200730 4.8 vs 2.0 -- -- -- -- --
Laurent-Puig 200916 7.9 vs 6.5 -- 0.280 19.7 vs 13.9 -- 0.180
Mancuso 200832 6.2 vs 3.2 -- 0.003 -- -- --
Perrone 200924 6 vs 5 -- -- -- -- --
Personeni 200833 5.5 vs 4 -- 0.25 10 vs 8.3 -- 0.037
Razis 200834 8.7 vs 6.4-6.9* 0.82 NS -- -- --
Sartore-Bianchi 200717 -- -- 0.039 -- -- 0.015
Sastre 200935 4.9 vs 2.6 -- 0.03 11.1 -- --
Scartozzi 200936 7.7 vs 2.9 -- 0.04 16 vs 9.5 -- 0.2
Tol 201037 9.5 vs 10.4 -- 0.19 21.9 vs 22.0 -- 0.65
  1. PFS, progression-free survival; mo, month; GCN+, increased gene copy number; GCN-, non-increased gene copy number; HR, hazard ratio; OS, overall survival; --, not available; NS, not significant (without detailed numerical values).
  2. * The original studies did not specify whether the number was “mean” or “median”.